Sick & Tired: Recognizing and Treating Fatigue in Persons With Multiple Sclerosis
This program is worth up to 1.0 CME credits.
Fatigue is the most commonly reported symptom in persons with Multiple Sclerosis. Fatigue interferes with sustained usual function, and is a significant cause of loss of employment and disability in otherwise unimpaired persons with MS. Additionally, contributing factors, such as other symptoms due to MS and co-morbidities that can contribute to and worsen primary MS fatigue, need to be addressed as well. Despite its prevalence, primary MS fatigue is often under recognized and treated in the MS population. This course includes information about the presentation and mechanisms of MS fatigue, as well as treatment strategies for both primary MS fatigue and contributing factors.
Up to 1.0 CME credit
*Free access is limited to one course at a time for eligible members.
As a result of this program the learner will:
Identify fatigue in persons with MS, distinguish between primary and secondary causes of fatigue, and implement effective management for this symptom. Specifically:
- Identify fatigue in persons with MS
- Distinguish between primary and secondary causes of fatigue
- Implement the appropriate management for fatigue in persons with MS
- Patient Care
- Interpersonal and Communication Skills
- Medical Knowledge
Date of Release
July 13, 2012
This module is eligible for CME credits for three years from the release date.
Confidentiality of Data
All material © American Academy of Neurology Institute unless otherwise indicated. All rights reserved.
Faculty & Disclosures
BARBARA S. GIESSER, MD, FAAN
Clinical Professor of Neurology
David Geffen School of Medicine
*Dr. Giesser has nothing to disclose.
Unlabeled Use DisclosureThe use of modafinil, armodafinil, anti-depressants and amantadine for treatment of MS fatigue are off label. The use of anti-depressants and anticonvulsants for treatment of neuropathic pain are off label. The use of diazepam for spasticity is off label. The use of amitriptyline for nocturia is off label. The use of chemotherapeutic agents (other than mitoxantrone) for disease modifying therapy is off label.
Distance Learning Subcommittee, Chair
A. GORDON SMITH, MD, FAAN
University of Utah Department of Neurology
Salt Lake City, Utah
*Dr. Smith has received personal compensation for activities with Allergan, Baxter Bioscience, Merz, Pfizer and NeurogesX as a consultant..
Sylvia Klineova, MD
CGD Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
*Dr. Klineova has received personal compensation for activities with Teva Neuroscience as a scientific advisory board member.
Tracy King, MA, Senior Manager, Education
*Ms. King has nothing to disclose.
Jodi Brenden Amir, Program Manager, Distance Learning
*Ms. Brenden Amir has nothing to disclose.
Susan Rodmyre, Director, Education
*Ms. Rodmyre has nothing to disclose.
Kurt Wiersma, Senior Manager, Web Development
*Mr. Wiersma has nothing to disclose.
Lori Strachota, Program Manager, Conference Management, Registration
*Ms. Strachota has nothing to disclose.